查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916929

寡核苷酸療法市場按治療領域、技術、寡核苷酸化學、遞送方法、給藥途徑、產品類型和最終用戶分類－2026-2032年全球預測

Oligonucleotide Therapeutics Market by Therapeutic Area, Technology, Oligonucleotide Chemistry, Delivery Method, Route Of Administration, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，寡核苷酸療法市場價值將達到 223.4 億美元，到 2026 年將成長至 237.3 億美元，複合年成長率為 6.90%，到 2032 年將達到 356.5 億美元。

關鍵市場統計數據
基準年 2025 223.4億美元
預計年份：2026年 237.3億美元
預測年份 2032 356.5億美元
複合年成長率 (%) 6.90%

明確闡述不斷發展的化學、遞送平台、監管動態和商業策略如何重塑寡核苷酸療法

寡核苷酸療法已從一項科學創新發展成為精準醫療的核心支柱，這得益於其不斷提升的臨床療效和技術成熟度。過去十年間，化學修飾、遞送載體和標靶定序技術的進步，使得反義寡核苷酸、siRNA、miRNA調變器相關療法從小眾研究工具發展成為多種疾病領域的實用治療選擇。本文概述了目前的研究現狀、影響其應用推廣的科學和商業性因素，以及相關人員為實現持續價值所必須克服的關鍵轉折點。

核苷酸化學、遞送方式、臨床檢驗和策略合作的最新進展正在共同重塑治療的可能性。

寡核苷酸療法領域正經歷著由科學突破和商業性需求共同驅動的變革。諸如鎖核酸、胜肽核酸和新一代硫代磷酸酯骨架等化學創新顯著提高了核酸酶抗性和靶向特異性，拓寬了治療窗口並降低了給藥頻率。同時，遞送技術也突破了全身暴露的限制，發展出更為精準的遞送方式，例如用於肝臟標靶化的GalNAc偶聯、可實現廣泛組織分佈的改良脂質奈米顆粒，以及用於中樞神經系統和眼科的特異性病毒和非病毒載體。這些技術進步使研發人員能夠將以往難以攻克的標靶轉化為可行的治療性介入。

評估美國關稅政策變化在2025年前對寡核苷酸研發供應鏈、採購和製造韌性的營運和策略影響

2025年，美國關稅政策變化帶來的累積影響，正日益增加寡核苷酸療法研發和生產商的營運及策略複雜性。影響關鍵投入品（例如特種核苷亞磷醯胺、修飾核苷酸和特定試劑盒）的關稅，推高了外包合成和內部生產的成本。為此，供應鏈管理人員正擴大實施供應商最佳化、雙源採購策略，並提高對上游投入品的透明度，以降低風險並確保關鍵計劃的連續性。這些調整優先考慮供應商合格和長期合約的簽訂，而非短期價格最佳化。

全面的細分分析揭示了治療標靶、技術類別、化學選擇、遞送途徑、給藥途徑、最終用戶和產品類型之間的相互作用。

從細緻的細分觀點，不同治療標靶、技術類型、化學選擇、給藥途徑、給藥方法、最終用戶和產品類型所帶來的機會和技術要求各不相同。按治療領域分類，項目涵蓋心血管疾病、感染疾病、代謝性疾病治療、神經病學（重點關注阿茲海默症、Duchenne氏肌肉失養症和亨廷頓病）、腫瘤學（包括骨髓惡性腫瘤和固態腫瘤） 、眼科以及叢集罕見疾病治療，例如BETA-地中海貧血、遺傳性高膽固醇症和脊髓性肌萎縮症。這些治療領域的差異影響著標靶檢驗策略、患者群體可及性考量以及監管路徑。

詳細分析美洲、歐洲、中東和非洲以及亞太地區的區域趨勢，以及監管合規、製造地和市場進入的戰略要務。

區域趨勢顯著影響寡核苷酸療法的研發重點、監管路徑、報銷環境和供應鏈策略。在美洲，監管機構正日益透過加速核准支持針對嚴重和危及生命的疾病的新型治療方法，而商業生態系統則強調生物技術公司與契約製造之間的合作，以加速從臨床到商業化的轉化。該地區的勞動力市場、投資者興趣和完善的製藥基礎設施有利於臨床項目的快速迭代，但研發人員必須應對不同支付方和政府系統報銷政策的差異。

專有化學技術、遞送平台、生產能力和策略合作夥伴關係如何幫助寡核苷酸療法領域建立永續的競爭優勢

寡核苷酸療法生態系統中的競爭優勢取決於專有化學技術、遞送平台、卓越的生產製造流程和策略聯盟的結合。主要企業透過持續投資平台知識產權來實現差異化，例如透過化學修飾支架改善藥物動力學，或開發實現組織特異性的遞送偶聯物。同時，合約開發和生產機構 (CDMO) 提供從大規模固相合成到先進純化和分析測試等專業的寡核苷酸技術，是加速產品研發管線和確保商業化供應的關鍵促進者。

切實可行、影響深遠的策略行動，旨在幫助企業強化平台、保障供應鏈安全、吸引早期支付者並擴大寡核苷酸專案的生產規模。

產業領導者可以採取切實可行的措施，在寡核苷酸療法領域獲得策略優勢並加速專案成熟。首先，投資差異化平台，將最佳化的化學方法與檢驗的遞送系統結合，以降低研發風險並創建更清晰的監管路徑。其次，優先考慮供應鏈的韌性，具體措施包括：對關鍵原料的多個供應商進行資格認證；考慮區域性製造地以降低貿易風險；以及簽訂長期採購協議，使合作夥伴之間的獎勵保持一致。

採用嚴謹的混合調查方法方法，結合專家訪談、文獻回顧、專利分析和情境檢驗，為策略決策提供支援。

本分析的調查方法結合了多層次的證據綜合與檢驗。主要研究包括對藥物發現、臨床開發、監管事務和生產領域的專家進行結構化訪談，以及與參與寡核苷酸計劃的採購和供應鏈經理進行諮詢。次要研究整合了同行評審文獻、監管指導文件和專利申請，以追蹤技術演進軌跡並識別持續存在的技術挑戰。交叉檢驗工作將定性研究結果與監管先例和生產實踐進行比較，以確保其可靠性。

概述重點指出，整合技術、營運和商業性策略將決定哪些寡核苷酸計畫能夠拓展到永續的治療領域。

總之，寡核苷酸療法正處於一個轉折點，科學進步、遞送方式改進、化學技術日趨成熟以及法規結構的不斷完善正在匯聚，共同開拓新的治療領域。技術創新與商業策略的結合已成為決定哪些項目能夠成功從概念驗證過渡到永續治療產品線的關鍵因素。那些能夠整合平台差異化、供應鏈韌性、監管前瞻性和生產規模的企業，將更有利於獲取長期價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 寡核苷酸療法市場依治療領域分類

  • 循環系統
  • 感染疾病
  • 代謝性疾病
  • 神經病學
    • 阿茲海默症
    • Duchenne氏肌肉失養症
    • 亨丁頓舞蹈症
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤
  • 眼科
  • 罕見疾病
    • BETA-地中海型貧血
    • 遺傳性高膽固醇症
    • 脊髓性肌肉萎縮症

9. 按技術分類的寡核苷酸療法市場

  • 反義寡核苷酸
    • RNase H 依賴型
    • 空間位阻
  • 適體
  • CpG寡脫氧核苷酸
  • miRNA
    • 微型RNA抑制劑
    • miRNA模擬物
  • siRNA
    • 化學改性
    • 不合格的

10. 寡核苷酸治療市場（依寡核苷酸化學分類）

  • 2'-O-甲基RNA
  • 鎖核酸
  • 嗎啉代寡聚物
  • 胜肽核酸
  • 硫代磷酸酯寡核苷酸

第11章 寡核苷酸療法市場依給藥方式分類

  • 共軛物
  • 直接注射
  • 電穿孔
  • 脂質奈米顆粒
  • 病毒載體

12. 寡核苷酸療法市場依給藥途徑分類

  • 吸入
  • 肌肉內注射
  • 靜脈注射
  • 口服
  • 皮下注射

13. 寡核苷酸療法市場（依產品類型分類）

  • 診斷試劑
  • 研究試劑
  • 治療藥物

第14章 寡核苷酸療法市場（以最終用戶分類）

  • 門診治療中心
  • 醫院
  • 製藥公司
  • 研究所

15. 各地區寡核苷酸療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 寡核苷酸療法市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國寡核苷酸療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國寡核苷酸療法市場

第19章 中國寡核苷酸療法市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Biogen Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Nitto Denko Avecia, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regulus Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-AE420CB153FF

The Oligonucleotide Therapeutics Market was valued at USD 22.34 billion in 2025 and is projected to grow to USD 23.73 billion in 2026, with a CAGR of 6.90%, reaching USD 35.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.34 billion
Estimated Year [2026] USD 23.73 billion
Forecast Year [2032] USD 35.65 billion
CAGR (%) 6.90%

A crisp orientation to how evolving chemistry, delivery platforms, regulatory evolution, and commercial strategy are reshaping oligonucleotide therapeutics

Oligonucleotide therapeutics have moved from scientific novelty to a central pillar of precision medicine portfolios, driven by expanding clinical validation and technological maturation. Over the past decade, advances in chemical modification, delivery vehicles, and targeted sequencing have elevated antisense oligonucleotides, siRNA, miRNA modulators, and related modalities from niche investigational tools to viable therapeutic options across multiple disease classes. This introduction outlines the current landscape, the scientific and commercial drivers shaping adoption, and the critical inflection points that industry stakeholders must navigate to realize durable value.

The field now integrates sophisticated nucleotide chemistries that enhance stability and target affinity with delivery strategies that broaden tissue reach beyond the liver. Regulatory frameworks have evolved in parallel, accommodating expedited pathways for severe and rare diseases while imposing rigorous manufacturing and quality standards. Simultaneously, biopharma and contract development organizations are investing in scalable synthesis and analytical platforms to address the unique production challenges of oligonucleotides. Consequently, corporate strategies increasingly emphasize platform differentiation, intellectual property stewardship, and strategic alliances to combine therapeutic expertise with delivery innovation.

As the modality crosses therapeutic boundaries from neurology and rare genetic disorders into oncology and metabolic disease, stakeholders must balance therapeutic ambition with pragmatic operational planning. This introduction sets the stage for a deeper analysis of transformative shifts, trade policy impacts, segmentation nuance, regional dynamics, competitive positioning, and recommended actions for leaders seeking to capitalize on the maturation of oligonucleotide therapeutics.

How recent advances in nucleotide chemistries, delivery modalities, clinical validation, and strategic partnerships are collectively redefining therapeutic possibilities

The landscape for oligonucleotide therapeutics is experiencing transformative shifts driven by converging scientific breakthroughs and commercial imperatives. Chemical innovations such as locked nucleic acids, peptide nucleic acids, and next-generation phosphorothioate backbones have materially improved nuclease resistance and target specificity, thereby extending therapeutic windows and reducing dosing frequency. Concurrently, delivery technologies have advanced from systemic exposure constraints to more precise approaches including GalNAc conjugation for hepatic targeting, lipid nanoparticle refinements that permit broader tissue distribution, and viral or non-viral vectors tailored for central nervous system and ocular delivery. These technical strides are enabling developers to reframe previously intractable targets as achievable therapeutic interventions.

At the same time, the clinical evidence base has shifted perceptions of feasibility across therapeutic areas. Neurology has emerged as a proving ground for central nervous system delivery strategies, while oncology programs increasingly leverage oligonucleotide constructs to modulate oncogenic drivers and immune pathways. The development ecosystem is also evolving: strategic partnerships between biotech innovators and established pharmaceutical manufacturers are becoming more transactional and purpose-built, focusing on rapid scale-up, supply continuity, and regulatory alignment. Investment patterns reflect a maturing ecosystem, with capital directed not only to clinical-stage assets but also to platform technologies and manufacturing capacity expansions that underpin long-term commercialization.

These shifts create both opportunity and complexity. Organizations that synchronize chemistry innovation with scalable delivery and robust manufacturing will gain competitive advantage, while those that underestimate regulatory expectations, quality control demands, and the intricacies of tissue-specific delivery risk costly setbacks. The cumulative effect is a market in transition, where technological differentiation and operational excellence jointly determine the trajectory of therapeutic success.

Evaluating the operational and strategic consequences of United States tariff policy shifts through 2025 on supply chains, sourcing, and manufacturing resilience in oligonucleotide development

The cumulative effects of tariff policy changes in the United States through 2025 have introduced an additional layer of operational and strategic complexity for developers and manufacturers of oligonucleotide therapeutics. Tariffs affecting key inputs such as specialized nucleoside phosphoramidites, modified nucleotides, and certain reagent classes have increased the cost base for outsourced synthesis and in-house production. In response, supply chain managers have intensified supplier rationalization, dual-sourcing strategies, and visibility into upstream inputs to mitigate risk and preserve continuity for critical campaigns. These adaptations have prioritized supplier qualification and long-term contractual commitments over short-term price optimization.

Tariff-driven inflation of input costs has also accelerated interest in regional manufacturing investments and capacity reallocation. Firms evaluating capital allocation decisions weigh the trade-offs between higher near-term capital expenditures for local production and the long-term benefits of supply security, regulatory alignment, and reduced exposure to cross-border trade frictions. At the same time, clinical development timelines can be sensitive to reagent and consumable availability, making procurement lead times an operational imperative rather than a back-office concern.

Policy volatility has pushed some organizations to reassess externalization strategies, favoring integrated partnerships that include upstream raw material sourcing and tiered supply agreements. Additionally, procurement and finance functions are collaborating more closely with R&D and manufacturing to model tariff scenarios and embed contingency plans into project timelines. While tariffs create headwinds, they also catalyze structural adjustments that can strengthen resilience and encourage investment in manufacturing sophistication and domestic supply capability.

Comprehensive segmentation analysis revealing how therapeutic focus, technology class, chemistry choices, delivery routes, administration pathways, end users, and product types interact

A nuanced segmentation lens reveals differentiated opportunities and technical requirements across therapeutic targets, technology types, chemistry options, delivery routes, administration modalities, end-users, and product categories. When segmented by therapeutic area, programs span cardiovascular disease, infectious disease, metabolic disorder interventions, neurology with focused attention on Alzheimer's disease, Duchenne muscular dystrophy, and Huntington's disease, oncology addressing both hematological malignancies and solid tumors, ophthalmology initiatives, and a cluster of rare disease approaches that include beta thalassemia, familial hypercholesterolemia, and spinal muscular atrophy. These therapeutic distinctions shape target validation strategies, patient population access considerations, and regulatory pathways.

Breaking down the landscape by technology, the field encompasses antisense oligonucleotides-distinguished by RNase H dependent mechanisms and steric blocking modalities-aptamers, CpG oligodeoxynucleotides, microRNA therapeutics encompassing both inhibitors and mimics, and siRNA constructs that range from chemically modified to unmodified forms. Each technology class imposes unique demands on design optimization, potency thresholds, and safety profiling. Chemistry selection further refines those demands: options such as 2'-O-methyl RNA, locked nucleic acids, morpholino oligomers, peptide nucleic acids, and phosphorothioate oligonucleotides present trade-offs among stability, affinity, immunogenicity, and manufacturability.

Delivery method segmentation includes conjugates, direct injection approaches, electroporation, lipid nanoparticles, and viral vectors, while routes of administration range from inhalation and intramuscular to intravenous, oral, and subcutaneous delivery. End users span ambulatory care centers, hospitals, pharmaceutical companies, and research institutes, each with distinct procurement models, infrastructure needs, and regulatory expectations. Product types differentiate diagnostics, research reagents, and therapeutic assets, which in turn influence commercialization strategies, reimbursement considerations, and manufacturing quality systems. Integrating these segmentation layers enables targeted portfolio planning and more precise go-to-market strategies aligned with technical feasibility and clinical priorities.

Detailed regional dynamics and strategic imperatives for regulatory engagement, manufacturing placement, and market access across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence development priorities, regulatory pathways, reimbursement landscapes, and supply chain strategies for oligonucleotide therapeutics. In the Americas, regulatory agencies have increasingly accommodated novel modalities through expedited pathways for serious and life-limiting conditions, and commercial ecosystems emphasize partnerships between biotech innovators and contract manufacturers to accelerate clinical-to-commercial transitions. The labor market, investor appetite, and established pharma infrastructure in the region drive rapid iteration of clinical programs, though developers must navigate reimbursement variability across payers and public systems.

Europe, Middle East & Africa presents a mosaic of regulatory regimes where centralized approval pathways coexist with country-level access constraints. Stakeholders operating across this region contend with heterogenous pricing and reimbursement frameworks, divergent clinical practice patterns, and varying levels of manufacturing capacity. Consequently, market access strategies require sophisticated evidence generation plans and early engagement with payers and health technology assessment bodies to align clinical endpoints with value demonstration.

Asia-Pacific combines rapidly growing biotech hubs with region-specific scientific strengths and manufacturing scale. Several countries in the region have invested in capacity expansion for oligonucleotide synthesis and biologics manufacturing, offering competitive cost structures and strong technical talent pools. However, differences in regulatory expectations and clinical trial infrastructure necessitate adaptive development strategies and localized regulatory affairs expertise. Together, these regional contours demand that developers tailor clinical, manufacturing, and commercial plans to reflect distinct regulatory regimes, payer landscapes, and supply chain realities.

How proprietary chemistries, delivery platforms, manufacturing capability, and strategic alliances are creating durable competitive moats in oligonucleotide therapeutics

Competitive positioning in the oligonucleotide therapeutics ecosystem is defined by a combination of proprietary chemistries, delivery platforms, manufacturing excellence, and strategic partnerships. Leading organizations differentiate through sustained investment in platform intellectual property, whether that is a chemically modified backbone that improves pharmacokinetics or a delivery conjugate that enables tissue specificity. At the same time, contract development and manufacturing organizations that offer specialized oligonucleotide capabilities-from large-scale solid-phase synthesis to advanced purification and analytical testing-serve as critical enablers for pipeline acceleration and commercial supply.

Strategic alliances between small biotech innovators and larger pharmaceutical or manufacturing partners have become a prevalent model to bridge capability gaps, while mergers and acquisitions continue to reconfigure competitive landscapes by consolidating platform technologies or bolstering manufacturing scale. Companies with integrated capabilities that span discovery, manufacturing, and regulatory affairs gain an advantage in compressing time-to-clinic and de-risking later-stage development. Conversely, firms that rely excessively on single-source suppliers or narrow technology portfolios face heightened vulnerability to supply disruptions and competitive displacement.

A resilient competitive strategy now also incorporates talent acquisition in specialized disciplines such as oligonucleotide analytics, regulatory science for nucleotide therapeutics, and GMP manufacturing of modified nucleotides. Organizations that cultivate cross-functional expertise and embed continuous process improvement within quality systems are better positioned to translate scientific innovation into reliable, scalable commercial outcomes.

Practical, high-impact strategic actions for companies to strengthen platforms, secure supply chains, engage payers early, and scale manufacturing for oligonucleotide programs

Industry leaders can take specific, actionable steps to secure strategic advantage and accelerate program maturation within the oligonucleotide therapeutics domain. First, invest in platform differentiation that pairs optimized chemistries with validated delivery systems to reduce development risk and create clearer regulatory pathways. Second, prioritize supply chain resilience by qualifying multiple suppliers for critical raw materials, considering regional manufacturing footprints to mitigate trade exposure, and establishing long-term procurement agreements that align incentives across partners.

Third, embed regulatory and payer engagement early in program design to ensure that clinical endpoints and evidence generation plans anticipate real-world access considerations. Fourth, cultivate strategic partnerships that close capability gaps-particularly in large-scale synthesis, advanced analytics, and specialized delivery vectors-rather than relying solely on ad hoc contracting. Fifth, develop integrated talent strategies to attract and retain expertise in oligonucleotide chemistry, GMP production, and regulatory science, while investing in continuous training and knowledge transfer mechanisms. Finally, adopt agile project management and scenario planning to respond quickly to policy shifts, supply chain disruptions, and competitive moves, thereby preserving runway and protecting program timelines.

Taken together, these recommendations form a coherent playbook for organizations seeking to convert scientific breakthroughs into sustainable therapeutic franchises, balancing innovation with operational rigor and commercial foresight.

A rigorous mixed-methods research methodology combining expert interviews, literature synthesis, patent analysis, and scenario-based validation to support strategic decision making

The research methodology underpinning this analysis combined a layered approach to evidence synthesis and validation. Primary research included structured interviews with domain experts across discovery, clinical development, regulatory affairs, and manufacturing as well as consultations with procurement and supply chain leads involved in oligonucleotide projects. Secondary research integrated peer-reviewed literature, regulatory guidance documents, and patent filings to trace technology evolution and identify enduring technical challenges. Cross-validation exercises compared qualitative insights with regulatory precedent and manufacturing practice to ensure robustness.

Analytical methods involved thematic coding of expert interview data to reveal recurring operational risks and strategic priorities, followed by scenario analysis to map the implications of tariff shifts, delivery breakthroughs, and regulatory changes. Technology readiness assessments were used to appraise the maturity of chemistries and delivery modalities, and capability gap analyses evaluated where investment would most effectively reduce development risk. All findings were synthesized into actionable recommendations and risk mitigation frameworks intended for executive stakeholders and technical teams alike.

Quality assurance processes included triangulation across multiple data sources, peer review by independent domain specialists, and iterative revisions based on stakeholder feedback. The methodology emphasizes transparency in assumptions, traceability of evidence, and pragmatic framing of recommendations to facilitate decision-making under uncertainty.

Concluding synthesis emphasizing how integrated technical, operational, and commercial strategies will determine which oligonucleotide programs scale into enduring therapeutic franchises

In conclusion, oligonucleotide therapeutics stand at an inflection point where scientific progress, improved delivery modalities, refined chemistries, and evolving regulatory frameworks collectively unlock new therapeutic territories. The intersection of technical innovation and commercial strategy is now the primary determinant of which programs will successfully transition from proof-of-concept to sustainable therapeutic franchises. Organizations that integrate platform differentiation, supply chain resilience, regulatory foresight, and manufacturing scale will be best positioned to capture long-term value.

Policy factors such as tariff changes and regional regulatory variability have heightened the importance of operational planning and localized strategy. Meanwhile, segmentation insights across therapeutic areas, technologies, chemistries, delivery routes, administration types, end users, and product categories reveal that a one-size-fits-all approach is no longer viable. Instead, targeted, data-informed strategies that align scientific feasibility with real-world access and manufacturing realities are essential.

Ultimately, the pathway to success requires balancing ambitious clinical goals with disciplined execution. Stakeholders that move decisively to shore up technical, operational, and commercial capabilities will find themselves well placed to lead the next wave of oligonucleotide therapeutic innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oligonucleotide Therapeutics Market, by Therapeutic Area

  • 8.1. Cardiovascular
  • 8.2. Infectious Diseases
  • 8.3. Metabolic Disorders
  • 8.4. Neurology
    • 8.4.1. Alzheimer's Disease
    • 8.4.2. Duchenne Muscular Dystrophy
    • 8.4.3. Huntington's Disease
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
    • 8.5.2. Solid Tumors
  • 8.6. Ophthalmology
  • 8.7. Rare Diseases
    • 8.7.1. Beta Thalassemia
    • 8.7.2. Familial Hypercholesterolemia
    • 8.7.3. Spinal Muscular Atrophy

9. Oligonucleotide Therapeutics Market, by Technology

  • 9.1. Antisense Oligonucleotide
    • 9.1.1. RNase H Dependent
    • 9.1.2. Steric Blocking
  • 9.2. Aptamer
  • 9.3. CpG Oligodeoxynucleotide
  • 9.4. Mirna
    • 9.4.1. Mirna Inhibitors
    • 9.4.2. Mirna Mimics
  • 9.5. Sirna
    • 9.5.1. Chemically Modified
    • 9.5.2. Unmodified

10. Oligonucleotide Therapeutics Market, by Oligonucleotide Chemistry

  • 10.1. 2'-O-Methyl RNA
  • 10.2. Locked Nucleic Acid
  • 10.3. Morpholino Oligomers
  • 10.4. Peptide Nucleic Acid
  • 10.5. Phosphorothioate Oligonucleotides

11. Oligonucleotide Therapeutics Market, by Delivery Method

  • 11.1. Conjugates
  • 11.2. Direct Injection
  • 11.3. Electroporation
  • 11.4. Lipid Nanoparticles
  • 11.5. Viral Vectors

12. Oligonucleotide Therapeutics Market, by Route Of Administration

  • 12.1. Inhalation
  • 12.2. Intramuscular
  • 12.3. Intravenous
  • 12.4. Oral
  • 12.5. Subcutaneous

13. Oligonucleotide Therapeutics Market, by Product Type

  • 13.1. Diagnostics
  • 13.2. Research Reagents
  • 13.3. Therapeutics

14. Oligonucleotide Therapeutics Market, by End User

  • 14.1. Ambulatory Care Centers
  • 14.2. Hospitals
  • 14.3. Pharmaceutical Companies
  • 14.4. Research Institutes

15. Oligonucleotide Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Oligonucleotide Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Oligonucleotide Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Oligonucleotide Therapeutics Market

19. China Oligonucleotide Therapeutics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Agilent Technologies, Inc.
  • 20.6. Alnylam Pharmaceuticals, Inc.
  • 20.7. Arrowhead Pharmaceuticals, Inc.
  • 20.8. Biogen Inc.
  • 20.9. Dicerna Pharmaceuticals, Inc.
  • 20.10. Gilead Sciences, Inc.
  • 20.11. Ionis Pharmaceuticals, Inc.
  • 20.12. Merck & Co., Inc.
  • 20.13. Merck KGaA
  • 20.14. Moderna, Inc.
  • 20.15. Nitto Denko Avecia, Inc.
  • 20.16. Novartis AG
  • 20.17. Pfizer Inc.
  • 20.18. Regulus Therapeutics, Inc.
  • 20.19. Sarepta Therapeutics, Inc.
  • 20.20. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY BETA THALASSEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY BETA THALASSEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RNASE H DEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RNASE H DEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RNASE H DEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY STERIC BLOCKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY STERIC BLOCKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY STERIC BLOCKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY APTAMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY APTAMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY APTAMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CPG OLIGODEOXYNUCLEOTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CPG OLIGODEOXYNUCLEOTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CPG OLIGODEOXYNUCLEOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA MIMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA MIMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA MIMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CHEMICALLY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CHEMICALLY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CHEMICALLY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY UNMODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY UNMODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY UNMODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY 2'-O-METHYL RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY 2'-O-METHYL RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY 2'-O-METHYL RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LOCKED NUCLEIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LOCKED NUCLEIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LOCKED NUCLEIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MORPHOLINO OLIGOMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MORPHOLINO OLIGOMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MORPHOLINO OLIGOMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE NUCLEIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE NUCLEIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE NUCLEIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIRECT INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIRECT INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 289. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2032 (USD MILLION)
  • TABLE 294. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY MIRNA, 2018-2032 (USD MILLION)
  • TABLE 295. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY SIRNA, 2018-2032 (USD MILLION)
  • TABLE 296. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 297. GCC OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE, BY DELIVE